Connect your AI

Septerna, Inc. SEPN Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

Ionis PharmaceuticalsIONS

-$20.82M-51.8%

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

Revenue$26.5M+12,011%

Operating income-$13.3M+48.7%

Net income-$8.6M+59.8%

EPS (diluted)-$0.19+61.2%

Balance sheet

Cash & equivalents$71.6M-65.9%

Total debt$23.1M-7.7%

Total equity$378.5M+195%

Total assets$569.7M+31.3%

Cash flow

Operating cash flow-$25.6M-9.8%

CapEx$832.0K+118%

Free cash flow-$26.5M-11.5%

Valuation

Market cap$1.62B+319%

Enterprise value$1.58B+1,325%

P/S22.5×-374×

Profitability

Operating margin-77.1%-38.4pp

Net margin-49.9%-24.9pp

FCF margin467.9%+243pp

Returns & leverage

Return on equity-12.2%—

Debt / equity0.1×—

Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Septerna, Inc.'s increase (decrease) in contract liabilities and current deferred income?: Septerna, Inc. (SEPN) reported increase (decrease) in contract liabilities and current deferred income of -$16.24M in Q1 2026.
How has Septerna, Inc.'s increase (decrease) in contract liabilities and current deferred income changed year-over-year?: Septerna, Inc.'s increase (decrease) in contract liabilities and current deferred income decreased by 138.6% year-over-year, from $42.05M to -$16.24M.